New analysis on Victoza reducing CV risk in type 2 diabetes

An analysis presented at the European Society of Cardiology (ESC) Annual Congress has shown that Victoza (liraglutide) reduces the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of whether they have had a heart attack or stroke or not.

The new analysis of the LEADER trial showed this comparison between Victoza, an approved a human glucagon-like peptide-1 (GLP-1) analogue from Danish diabetes giant Novo Nordisk (NOV: N), and placebo.

It was presented at the Barcelona conference just three days after the announcement that the US Food and Drug Administration (FDA) had approved a new indication for Victoza to reduce the risk of major adverse CV events in adults with type 2 diabetes and established CV disease, strengthening the position as a leader in the GLP-1 class against the likes of Jardiance (empagliflozin), from Boehringer Ingelheim and Eli Lilly (NYSE: LLY).